The global neuromodulation device market was valued at $5.9 billion in 2025. The market is expected to grow at a compound annual growth rate (CAGR) of 4.4%, reaching $8 billion by 2032.
This report covers spinal cord stimulation (SCS), deep brain stimulation (DBS), sacral nerve stimulation, vagus nerve stimulation, and gastric electric stimulation. The SCS segment is further analyzed by device type into generators and leads. The report quantifies procedure numbers, unit sales, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.
The market is expected to demonstrate steady growth over the forecast period, driven by increasing procedure volumes and expanding clinical applications across the five device categories. Unit sales are projected to grow at a solid pace, though growth rates moderate gradually as the market matures. Technological advancements in SCS, including extended battery life, device miniaturization, rechargeable implant systems, and new stimulation modalities such as high-frequency and burst stimulation, are sustaining strong underlying demand.
ASPs are expected to decrease slightly over the forecast period, reflecting pricing pressures and competitive dynamics within the market. Overall market value growth remains positive and is primarily volume-driven. Patient compliance with rechargeable device charging and patent constraints limiting access to high-frequency stimulation technology for certain competitors represent the primary structural limiters on market dynamics.
Market growth across the forecast period is primarily volume-driven, as unit sales increase across therapy areas while ASPs trend modestly downward due to pricing competition and market maturation. The pace of unit volume growth is expected to moderate gradually as the market moves through successive stages of maturity in established geographies. Despite this moderation, the market continues to show strong underlying demand as indications expand, physician adoption grows, and product innovations increase both patient eligibility and procedural confidence.
The SCS segment is experiencing the most active product innovation within the neuromodulation space. Advances in rechargeable generator technology, reductions in device size and weight, expanded programming options, and new stimulation modes including high-frequency and burst stimulation have broadened the clinical appeal of SCS and expanded the patient profiles for which it is considered appropriate. Wireless and minimally invasive injectable device formats are also entering the market, representing a next-generation delivery approach that could further expand adoption, particularly among patients or settings where traditional implantation procedures present a higher barrier.
The competitive landscape is moderately concentrated, with Medtronic, Abbott, and Boston Scientific holding leading positions alongside specialty companies including Nevro, which holds a differentiated position through its patented high-frequency stimulation technology. Pricing pressure from competitive dynamics and the transition to rechargeable systems, which carry lower replacement frequency, are both moderating ASP trajectories across the generator and leads segments while increasing the value proposition for patients who remain on therapy longer with fewer revision surgeries.
Abbott held the second-leading position in the neuromodulation device market in 2025. The company offers the Proclaim Elite recharge-free SCS system in two sizes, providing a primary cell option for patients who prefer a non-rechargeable alternative. Abbott also offers the Prodigy MRI SCS system, which is the company's smallest implantable pulse generator and incorporates BurstDR stimulation technology. Abbott remains the only competitor currently offering this specific type of burst stimulation device, providing a differentiated clinical position in the SCS market and supporting its competitive standing against larger market participants.
Boston Scientific was the third-leading competitor in the neuromodulation device market in 2025. The company offers four distinct products within the Precision line of spinal cord stimulation systems: the Montage, Spectra, Plus, and Novi. This range of SCS platform options allows Boston Scientific to address different patient needs and physician preferences across rechargeable and non-rechargeable configurations and across varying levels of programming sophistication. The breadth of the Precision portfolio supports coverage across multiple segments of the SCS market and reinforces Boston Scientific's competitive position alongside Medtronic and Abbott.
6 charts and 113 figures illustrating market segmentation and performance metrics.
Methodology Appendix, Abbreviation and Acronym Glossary explaining all data definitions and modeling assumptions.
Licensing options: single-user, site, and enterprise.
This report covers spinal cord stimulation (SCS), deep brain stimulation (DBS), sacral nerve stimulation, vagus nerve stimulation, and gastric electric stimulation. The SCS segment is further analyzed by device type into generators and leads. The report quantifies procedure numbers, unit sales, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.
The market is expected to demonstrate steady growth over the forecast period, driven by increasing procedure volumes and expanding clinical applications across the five device categories. Unit sales are projected to grow at a solid pace, though growth rates moderate gradually as the market matures. Technological advancements in SCS, including extended battery life, device miniaturization, rechargeable implant systems, and new stimulation modalities such as high-frequency and burst stimulation, are sustaining strong underlying demand.
ASPs are expected to decrease slightly over the forecast period, reflecting pricing pressures and competitive dynamics within the market. Overall market value growth remains positive and is primarily volume-driven. Patient compliance with rechargeable device charging and patent constraints limiting access to high-frequency stimulation technology for certain competitors represent the primary structural limiters on market dynamics.
Market Overview
The global neuromodulation device market encompasses a diverse set of implantable electrical stimulation therapies that modulate neural activity to treat a range of chronic conditions. Spinal cord stimulation is the largest and most commercially active segment, used primarily for the management of chronic pain. Deep brain stimulation addresses movement disorders such as Parkinson's disease and essential tremor. Sacral nerve stimulation targets bladder and bowel dysfunction, vagus nerve stimulation is used in epilepsy and treatment-resistant depression, and gastric electric stimulation provides therapy for gastroparesis. Together, these five modalities address a broad and growing chronic condition patient population across major global markets.Market growth across the forecast period is primarily volume-driven, as unit sales increase across therapy areas while ASPs trend modestly downward due to pricing competition and market maturation. The pace of unit volume growth is expected to moderate gradually as the market moves through successive stages of maturity in established geographies. Despite this moderation, the market continues to show strong underlying demand as indications expand, physician adoption grows, and product innovations increase both patient eligibility and procedural confidence.
The SCS segment is experiencing the most active product innovation within the neuromodulation space. Advances in rechargeable generator technology, reductions in device size and weight, expanded programming options, and new stimulation modes including high-frequency and burst stimulation have broadened the clinical appeal of SCS and expanded the patient profiles for which it is considered appropriate. Wireless and minimally invasive injectable device formats are also entering the market, representing a next-generation delivery approach that could further expand adoption, particularly among patients or settings where traditional implantation procedures present a higher barrier.
The competitive landscape is moderately concentrated, with Medtronic, Abbott, and Boston Scientific holding leading positions alongside specialty companies including Nevro, which holds a differentiated position through its patented high-frequency stimulation technology. Pricing pressure from competitive dynamics and the transition to rechargeable systems, which carry lower replacement frequency, are both moderating ASP trajectories across the generator and leads segments while increasing the value proposition for patients who remain on therapy longer with fewer revision surgeries.
Market Drivers
Technological Advancements
Continuous innovation across the SCS segment is sustaining strong demand and expanding the range of patients who are suitable candidates for therapy. Extended battery life in implantable rechargeable systems has significantly improved the value proposition for patients, with approvals for battery life of up to 11 years in certain products reducing the frequency of surgical replacements. While longer battery life reduces the number of replacement unit sales per patient, it expands the addressable population by making SCS a more attractive long-term option for patients who prefer not to rely on medication alone. Broader advancements in device miniaturization, decreasing device weight, and expanded wireless programming options are also improving patient experience and physician flexibility. Higher-frequency stimulation, burst stimulation, and wireless injectable device formats represent the leading edge of SCS innovation, with each modality offering distinct clinical profiles and expanding the therapeutic toolset available to implanting physicians.Increased Use of Rechargeable Implants
All major SCS manufacturers now offer rechargeable generator systems, and these products continue to grow in preference over primary cell (non-rechargeable) alternatives. Rechargeable generators require fewer revision surgeries over the life of the therapy because their batteries can be replenished externally, extending the useful implant life significantly compared to shorter-lived primary cell generators. This reduction in surgical revisions lowers long-term healthcare costs and improves the overall economics of SCS therapy, supporting broader adoption among physicians, payers, and patients who evaluate the cost of care over the full treatment period. Rechargeable generators are also notably less expensive than non-rechargeable alternatives at the point of implant, further supporting their adoption across a range of care settings and payer environments.Market Limiters
Patient Compliance
The shift toward rechargeable SCS devices, while beneficial from a cost and revision rate perspective, introduces a patient compliance requirement that is not present with primary cell generators. Rechargeable systems require patients to regularly charge their implanted device using an external charger, and failure to maintain this charging routine results in a reduction in therapy efficacy as battery levels decline. Patients who are non-compliant with charging schedules may experience symptom recurrence and reduced satisfaction with the therapy, which can result in discontinuation. This compliance burden may make rechargeable devices less suitable for certain patient populations, including elderly patients or those with limited manual dexterity, and represents a structural limitation on the ability of rechargeable systems to fully replace non-rechargeable alternatives across all patient profiles.Patent Infringement Constraints
Nevro has implemented its patented HF10 high-frequency therapy in its SCS systems since 2010, a technology that has received FDA labeling indicating superiority compared to traditional SCS therapy. In early 2019, Nevro initiated a patent infringement lawsuit against Stimwave, a company developing minimally invasive SCS devices that had enabled its systems to operate at 10 kHz. The lawsuit resulted in a partial injunction against Stimwave that limits Stimwave and other SCS competitors to stimulation frequencies below 3 kHz. This effectively leaves Nevro as the sole provider of paresthesia-free high-frequency SCS therapy at 10 kHz, creating a meaningful competitive moat in this clinically differentiated therapy segment and constraining the ability of other manufacturers to compete directly in the high-frequency stimulation space.Market Coverage and Data Scope
- Quantitative coverage: Procedure numbers, market size, market shares, market forecasts, growth rates, units sold, and average selling prices.
- Qualitative coverage: Growth trends, market limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, and technology trends shaping demand.
- Time frame: Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.
- Data sources: Primary interviews with neuromodulation device industry leaders and implanting physicians, regulatory data, hospital procurement data, import and export data, and the iData Research internal database.
- Care settings: Hospitals, ambulatory surgery centers, and pain management and neurology specialty clinics.
Markets Covered and Segmentation
The neuromodulation device market is analyzed across five therapy categories. Each is assessed by procedure volume, unit volume, ASP, and market value with historical and forecast data:
- Spinal Cord Stimulation (SCS) Market
- Device Type: Generators and Leads
- Deep Brain Stimulation (DBS) Market
- Sacral Nerve Stimulation Market
- Vagus Nerve Stimulation Market
- Gastric Electric Stimulation Market
Competitive Analysis
Medtronic was the leader in the global neuromodulation device market in 2025. The company competes through its InterStim therapy system product line, a sacral nerve stimulation platform used to treat overactive bladder, non-obstructive urinary retention, and bowel dysfunction. Medtronic's broad neuromodulation portfolio, established clinical training programs, and extensive commercial infrastructure across major global markets underpin its leading market position. The company's scale across multiple neuromodulation modalities provides diversified revenue and a comprehensive presence across the five therapy areas covered in this report.Abbott held the second-leading position in the neuromodulation device market in 2025. The company offers the Proclaim Elite recharge-free SCS system in two sizes, providing a primary cell option for patients who prefer a non-rechargeable alternative. Abbott also offers the Prodigy MRI SCS system, which is the company's smallest implantable pulse generator and incorporates BurstDR stimulation technology. Abbott remains the only competitor currently offering this specific type of burst stimulation device, providing a differentiated clinical position in the SCS market and supporting its competitive standing against larger market participants.
Boston Scientific was the third-leading competitor in the neuromodulation device market in 2025. The company offers four distinct products within the Precision line of spinal cord stimulation systems: the Montage, Spectra, Plus, and Novi. This range of SCS platform options allows Boston Scientific to address different patient needs and physician preferences across rechargeable and non-rechargeable configurations and across varying levels of programming sophistication. The breadth of the Precision portfolio supports coverage across multiple segments of the SCS market and reinforces Boston Scientific's competitive position alongside Medtronic and Abbott.
Technology and Practice Trends
- Extended battery life: Approvals for implantable SCS battery life of up to 11 years reduce replacement procedure frequency and expand the long-term value proposition of SCS therapy for patients and payers.
- Rechargeable generator adoption: Rechargeable SCS generators are displacing primary cell alternatives due to lower revision rates, reduced long-term cost, and lower upfront device price, and are now offered by all major manufacturers.
- Device miniaturization: Reductions in generator size and weight are improving patient comfort and expanding the eligible implant population to include patients for whom earlier generation device profiles presented fit or implant site challenges.
- High-frequency stimulation: Nevro's patented HF10 therapy at 10 kHz delivers paresthesia-free stimulation and holds FDA superiority labeling over traditional SCS, maintaining Nevro's unique position in the high-frequency segment.
- Burst stimulation: BurstDR technology, currently exclusive to Abbott's SCS platform, mimics natural neural firing patterns and provides an additional stimulation mode differentiation in the SCS competitive landscape.
- Wireless and injectable devices: Minimally invasive wireless injectable SCS devices represent an emerging delivery format that may expand the candidate pool to patients or settings where conventional implant procedures present a higher clinical or logistical barrier.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.Deliverables
155 pages of detailed narrative analysis, tables, and figures.6 charts and 113 figures illustrating market segmentation and performance metrics.
Methodology Appendix, Abbreviation and Acronym Glossary explaining all data definitions and modeling assumptions.
Licensing options: single-user, site, and enterprise.
Why This Report
- Where are the largest and fastest-growing opportunities across SCS, DBS, sacral nerve stimulation, vagus nerve stimulation, and gastric electric stimulation through 2032?
- How are rechargeable SCS generators, extended battery life, and device miniaturization reshaping product mix, revision cycles, and the long-term economics of SCS therapy?
- What is the commercial and clinical impact of Nevro's patented HF10 high-frequency stimulation technology, and how does the 3 kHz frequency constraint affect competitor product development strategies?
- How is burst stimulation technology differentiating the SCS competitive landscape, and what are the implications for physician preference and market share?
- Which device categories are gaining share across the five neuromodulation therapy areas, and how are clinical indication expansions driving incremental procedure volume?
- Which companies lead each segment and how are their product portfolios differentiated across stimulation modality, rechargeability, and device form factor?
- What is the outlook for ASP trends across generator and leads segments as rechargeable adoption grows and pricing competition intensifies?
- What are the key risks to market growth, including patient compliance challenges with rechargeable systems, patent constraints, and the pace of adoption in emerging markets?
Table of Contents
Research Methodology
Neuromodulation Device Market
List of Charts
List of Figures
